Time on boards
- Boards served
- 2
- Current seats
- 2
- Board service
- 5 years
- Director since
- 2023
5 years of board service in total across 2 boards, counting each seat separately. Longest: Exelixis Inc., 3 years.
Exelixis Inc.
Director
Ovid Therapeutics Inc.
Director
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| May 27, 2026 | Exelixis Inc. | Grant or award | +8,367 | — | — |
| Apr 7, 2026 | Ovid Therapeutics Inc. | Grant or award | +17,578 | $2.56 | $45,000 |
| Nov 12, 2025 | Exelixis Inc. | Open-market sale | −100,000 | $43.55 | $4,355,000 |
| May 29, 2025 | Exelixis Inc. | Grant or award | +9,812 | — | — |
| May 15, 2025 | Exelixis Inc. | Option exercise | +20,634 | $19.77 | $407,934 |
| May 15, 2025 | Exelixis Inc. | Open-market sale | −20,634 | $44.35 | $915,118 |
| May 15, 2025 | Exelixis Inc. | Option exercise | +15,874 | $20.50 | $325,417 |
| May 15, 2025 | Exelixis Inc. | Open-market sale | −15,874 | $44.35 | $704,012 |
| May 31, 2024 | Exelixis Inc. | Grant or award | +18,838 | — | — |
| May 20, 2024 | Exelixis Inc. | Option exercise | +11,686 | $19.57 | $228,695 |
| May 20, 2024 | Exelixis Inc. | Open-market sale | −11,437 | $21.00 | $240,177 |
| Jun 1, 2023 | Exelixis Inc. | Grant or award | +20,718 | — | — |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.